Latest news with #Vaxcyte
Yahoo
27-05-2025
- Business
- Yahoo
Here's Why Vaxcyte (PCVX) Sold Off in Q1
Carillon Tower Advisers, an investment management company, released its 'Carillon Eagle Small Cap Growth Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as Vaxcyte, Inc. (NASDAQ:PCVX). Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases. The one-month return of Vaxcyte, Inc. (NASDAQ:PCVX) was -1.09%, and its shares lost 52.68% of their value over the last 52 weeks. On May 23, 2025, Vaxcyte, Inc. (NASDAQ:PCVX) stock closed at $32.54 per share with a market capitalization of $4.198 billion. Carillon Eagle Small Cap Growth Fund stated the following regarding Vaxcyte, Inc. (NASDAQ:PCVX) in its Q1 2025 investor letter: "Vaxcyte, Inc. (NASDAQ:PCVX) is a leading biotechnology company focused on developing vaccines. The company is developing VAX24/VAX-31 for the prevention of pneumococcal disease in infants and adults. Phase 2 trial results for VAX-24 in infants were announced, demonstrating non-inferiority to another drug on nearly all serotypes tested. While the results were promising enough to proceed to phase 3, they were not as robust as previous VAX-24 trials. Additionally, the resignation of a key U.S. Food and Drug Administration leader, Dr. Peter Marks, shortly before the results were unveiled, raised concerns in the vaccine industry and contributed to a significant selloff in the stock. Despite these challenges, the company remains optimistic about the future of VAX-24 in phase 3 trials." A research scientist in a laboratory holding a vial of a biotechnology drug. Vaxcyte, Inc. (NASDAQ:PCVX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held Vaxcyte, Inc. (NASDAQ:PCVX) at the end of the first quarter, which was 50 in the previous quarter. While we acknowledge the potential of Vaxcyte, Inc. (NASDAQ:PCVX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Vaxcyte, Inc. (NASDAQ:PCVX) and shared the list of stocks that will bounce back according to analysts. The fund stated in its Q4 2024 investor letter that Vaxcyte, Inc. (NASDAQ:PCVX) underperformed due to uncertainty surrounding its key vaccine candidates amid political shifts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
27-05-2025
- Business
- Yahoo
Here's Why Vaxcyte (PCVX) Sold Off in Q1
Carillon Tower Advisers, an investment management company, released its 'Carillon Eagle Small Cap Growth Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as Vaxcyte, Inc. (NASDAQ:PCVX). Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases. The one-month return of Vaxcyte, Inc. (NASDAQ:PCVX) was -1.09%, and its shares lost 52.68% of their value over the last 52 weeks. On May 23, 2025, Vaxcyte, Inc. (NASDAQ:PCVX) stock closed at $32.54 per share with a market capitalization of $4.198 billion. Carillon Eagle Small Cap Growth Fund stated the following regarding Vaxcyte, Inc. (NASDAQ:PCVX) in its Q1 2025 investor letter: "Vaxcyte, Inc. (NASDAQ:PCVX) is a leading biotechnology company focused on developing vaccines. The company is developing VAX24/VAX-31 for the prevention of pneumococcal disease in infants and adults. Phase 2 trial results for VAX-24 in infants were announced, demonstrating non-inferiority to another drug on nearly all serotypes tested. While the results were promising enough to proceed to phase 3, they were not as robust as previous VAX-24 trials. Additionally, the resignation of a key U.S. Food and Drug Administration leader, Dr. Peter Marks, shortly before the results were unveiled, raised concerns in the vaccine industry and contributed to a significant selloff in the stock. Despite these challenges, the company remains optimistic about the future of VAX-24 in phase 3 trials." A research scientist in a laboratory holding a vial of a biotechnology drug. Vaxcyte, Inc. (NASDAQ:PCVX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held Vaxcyte, Inc. (NASDAQ:PCVX) at the end of the first quarter, which was 50 in the previous quarter. While we acknowledge the potential of Vaxcyte, Inc. (NASDAQ:PCVX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Vaxcyte, Inc. (NASDAQ:PCVX) and shared the list of stocks that will bounce back according to analysts. The fund stated in its Q4 2024 investor letter that Vaxcyte, Inc. (NASDAQ:PCVX) underperformed due to uncertainty surrounding its key vaccine candidates amid political shifts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?
We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments. The S&P 500 rose by 0.43%, while the tech-heavy Nasdaq added 0.27%. The blue-chip Dow Jones Industrial Average increased by 0.7% READ ALSO: 11 Best Stocks Under $15 to Buy According to Hedge Funds and 10 Most Profitable Cheap Stocks to Buy Now. As anticipated, the Federal Open Market Committee decided to keep its benchmark overnight borrowing rate unchanged in a range between 4.25% to 4.5%, where it has been since December. In its post-meeting statement, the Fed pointed out that the risks of both higher unemployment and higher inflation have risen. The Fed also said that uncertainty about the economic outlook has grown and that it will keep watching new data closely before making any changes. This announcement coincides with growing concerns about a global trade war that could send prices higher. This could make it difficult for the central bank to achieve its goal of bringing inflation down to 2%. During the post-decision press conference, Fed Chair Jerome Powell stated that if the recently announced large increases in tariffs remain in place, they could slow economic growth, push inflation up in the long run, and increase unemployment. Bloomberg reported on Wednesday that the Trump administration aims to end trade restrictions on AI. This helped boost some AI and tech stocks. However, earlier on Wednesday, President Trump told reporters that he is not ready to lower tariffs on China as a condition to start trade talks. This statement by the US President came ahead of meetings set to take place this weekend between US and Chinese officials in Switzerland to discuss trade issues. To compile our list of the 11 stocks that will bounce back according to analysts, we looked for stocks that have lost at least 30% year-to-date as of May 5, 2025. Next, we focused on the top stocks that analysts believe have the most potential for growth. To find stocks that will bounce back, we narrowed down our selection by looking for stocks that analysts believe will gain at least twice as much as they have lost year-to-date. Finally, we ranked the 11 stocks that will bounce back based on their average price target upside potential according to analysts as of May 5, 2025. Additionally, we mentioned the hedge fund sentiment surrounding each stock, which was taken from Insider Monkey's Q4 2024 database of more than 1,000 elite hedge funds. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A research scientist in a laboratory holding a vial of a biotechnology drug. Year-to-Date Performance: -58.85% Average Price Target Upside Potential According to Analysts: 304.03% Number of Hedge Fund Holders: 50 Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation that engineers, optimizes, and manufactures superior, high-fidelity vaccines. The company develops vaccines to prevent or treat bacterial infections like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Vaxcyte, Inc. (NASDAQ:PCVX) is one of the top stocks that will bounce back according to analysts. On April 22, Cantor Fitzgerald initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) with an 'Overweight' rating after the company showcased promising VAX-31 pneumococcal conjugate vaccine (PCV) data in adults last fall. Despite the fact that Vaxcyte, Inc. (NASDAQ:PCVX) is facing challenges, like mixed results from its VAX-24 pediatric vaccine and shifts in US vaccine policy, Cantor Fitzgerald still is optimistic about the company's long-term prospects. The firm's analysis noted that the company's programs are still years away from regulatory review. The adult VAX-31 is expected in 2027 while the pediatric strategy is expected in 2029. Cantor Fitzgerald suggests that by the time the company's products come under review, the current leadership and policy environment could change and help the company's trajectory. Vaxcyte, Inc. (NASDAQ:PCVX) has a strong position in the pneumococcal conjugate vaccine market, which is valued at over $8 billion, thanks to strong data from the adult VAX-31 trials. Additionally, Cantor Fitzgerald pointed out that the company has two ways to move forward with its pediatric vaccines with VAX-31 and a dose-optimized VAX-24. The firm's commentary suggests that the stock's current low price and market capitalization could bounce back if there are changes in the Health and Human Services (HHS), Food and Drug Administration (FDA), or Centers for Disease Control and Prevention (CDC) leadership and vaccine policy. Overall, PCVX ranks 1st on our list of stocks that will bounce back according to analysts. While we acknowledge the potential of PCVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PCVX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
01-05-2025
- Business
- Yahoo
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?
We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against other oversold NASDAQ stocks to buy right now. On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on CNBC's 'Squawk on the Street' to discuss market outlooks and what investors should look at in the current market circumstances. He opined that it is growth that investors should be worried about, not inflation. Cronk was of the view that the market will likely see better buying/entry opportunities in the coming weeks, and so it is essential to be careful when chasing equities too hard. There is a growing divide between sentiment and positioning, as we live in a geopolitical-first world where the rules of the game can change with stunning speed. Cronk further opined that many people overlook a key fact about tariffs, solely focusing on their inflationary nature. While tariffs are inflationary, they are blunt-force resets in prices and are not sustained inflationary. So, although companies need to be able to absorb the blunt force reset of prices and impact of margins, it's not like one continues to see the rate of change of inflation move meaningfully higher up from years one to two, three, and four. This trend only emerges when tariffs move meaningfully higher up over a period of time. READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 10 Best Stocks That Will Always Grow. Cronk also talked about how the president has been screaming at the Fed to slash interest rates. But it's not just the president; the bond market is doing the same. Fed cuts over a period of time are essential. However, according to Cronk, if the Fed shows up tomorrow and announces an emergency cut of sorts, markets wouldn't perceive it so well. The markets would take it as the Fed knowing something they do not, and the growth scare would grow more pervasive and problematic. This is why the Fed has to be careful about how they act. The Fed appears to be more concerned about inflation, and it has been consistent in that. If they switched to more growth concerns than inflation concerns, the markets would perceive them as more dovish. He said that we just saw the Fed's president saying that June could be on the table for a possible rate cut. The Fed is thus starting to lay the groundwork, and we would have to see how that narrative turns out. If it takes a more dovish approach, markets would perceive that in a well-timed, thoughtful way. Since April 1, nine of the eleven S&P gig sectors have revised their guidance lower. The problem is that out of the 20%- 25% of the reported earnings that the market has seen right now, less than 20% of them have been willing to give forward guidance. Therefore, Cronk highlighted that the guidance suspension is obviously problematic and important here. The market thus needs consumer discretionary stocks and industrials to hold up and tech to deliver. Our Methodology We used stock screeners to compile a list of NASDAQ stocks that experienced significant YTD performance declines. We then selected the 11 stocks with the highest analyst upside potential as of April 29, 2025. We also added the number of hedge fund holders for these stocks as of Q4 2024, sourcing hedge fund data from Insider Monkey's database. The list is sorted in ascending order of the upside potential. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A research scientist in a laboratory holding a vial of a biotechnology Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques. Needham analyst Joseph Stringer maintained a bullish stance on Vaxcyte, Inc. (NASDAQ:PCVX), giving it a Buy rating on April 1. The analyst said that the company's recent VAX-24 Phase 2 infant study data has bolstered confidence in its success with encouraging results. The overall expectations around the VAX-31 Phase 2 infant program are also positive, pointing to further advancements in their vaccine development pipeline. The analyst further reasoned that Vaxcyte, Inc. (NASDAQ:PCVX) is committed to expanding its product offerings, and the introduction of the VAX-XL program, which could potentially enhance its market position, corroborates that. These factors combined support a favorable outlook for the company's performance. Overall, PCVX ranks 1st on our list of oversold NASDAQ stocks to buy right now. While we acknowledge the potential for PCVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PCVX but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. So should Vaxcyte (NASDAQ:PCVX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at December 2024, Vaxcyte had cash of US$1.7b and no debt. Looking at the last year, the company burnt through US$572m. So it had a cash runway of about 3.1 years from December 2024. Importantly, analysts think that Vaxcyte will reach cashflow breakeven in 4 years. Essentially, that means the company will either reduce its cash burn, or else require more cash. Depicted below, you can see how its cash holdings have changed over time. See our latest analysis for Vaxcyte Vaxcyte didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. During the last twelve months, its cash burn actually ramped up 57%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. Given its cash burn trajectory, Vaxcyte shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Vaxcyte's cash burn of US$572m is about 14% of its US$4.1b market capitalisation. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted. It may already be apparent to you that we're relatively comfortable with the way Vaxcyte is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. On another note, Vaxcyte has 4 warning signs (and 1 which shouldn't be ignored) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
